Toronto, Ontario (Newsfile Corp. - October 14, 2021) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide an update on new appointments to support
Glow LifeTech Corp.: Glow LifeTech Secures Canadian Processing Facility, Begins Build-out to Produce Next-Generation Cannabis Ingredients
Glow or the
Company ), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to report that the Company has commenced the build-out and commissioning of licensed processing space ( Processing Space ) to bring a suite of fast-acting, high-absorption, water-soluble cannabis-based ingredients to the Canadian market. The Processing Space is licensed for the processing and sale of cannabis under the Canadian Cannabis Act.
Glow s MyCell® technology is a proprietary plant-based delivery system developed in Switzerland which dramatically improves the absorption, bioavailability and effectiveness of natural active compounds including cannabinoids, vitamins, botanicals and more. The Company has secured the processing space by way of a long term engagement with a licensed facility that provides Glow the necessary
Article content
The results, announced on May 7, 2021, demonstrate the mechanism of action of ArtemiC™ is to reduce inflammation and suppress the cytokine storm
2 – believed to be the one of the leading causes of mortality in COVID-19 patients
3. The results show that ArtemiC™ decreases the markers of inflammation (IFN-g, IL-1a and TNF-a), in the bronchoalveolar lavage fluid (BALF) of mice in the animal model of cytokine storm related to COVID-19. The clinical and preclinical results to date support ArtemiC™ being effective for addressing cytokine overproduction which is found in different variants and mutations of COVID-19.
“ArtemiC™ focuses on preventing and reducing the severity of the cytokine storm and hyper-inflammation induced by respiratory viruses, and since all current COVID-19 variants of concern may lead to a cytokine storm, the preclinical and clinical results support that ArtemiC™ should be effective on COVID-19 variants,” said Tom Glawdel, PhD, Chi
Glow LifeTech Announces Successful First Commercial Production of ArtemiC(TM) for Global Distributor and a Second Production Scaled to Meet Growing Global Demand streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.